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Pseudohypoaldosteronism (PHA) type I is a rare genetic disorder affecting one in 47,000-80,000 newborns [1,2]. Cheek and Perry [3] have addressed PHA type 1 for 
the 1st time in 1958. In 1980, Dillon et al. [4] reported more 
cases, and later in 1991, Hanukoglu explained 2 different types 
of inheritance pattern after a clinical investigation in nine 
patients [5]: An autosomal dominant type which is restricted to 
the kidney (also known as rPHA1) and an autosomal recessive 
type mostly presenting with more severe systemic symptoms 
(also called sPHA1) [6]. The rPHA1 is caused by mutations in 
the NR3C2 gene on chromosome 4q31.1, which is responsible for 
encoding mineralocorticoid receptors (MR) [7,8]. Furthermore, 
genetic assessments in patients with an autosomal recessive type 
of disease have shown that SCNN1A, SCNN1B, and SCNN1G 
mutations occur in amiloride-sensitive epithelial sodium channels 
(ENaC) [1,9-11]. The ENaC channels are also present in all 
aldosterone-responsive target organs such as the kidneys, colon, 
lungs, and sweat glands. This permanent resistance to aldosterone 
in these organs can lead to severe sodium wasting, hypovolemia, 
hyperkalemia, metabolic acidosis, and failure to thrive [12,13]. 
Affected patients also suffer from recurrent pulmonary infections 
in a pattern that is not distinguishable from cystic fibrosis [14].
Neonatal-onset disease is more common in autosomal dominant 
type; it might present with a variety of symptoms and may lead 
to fatal cardiac arrhythmias due to hypoaldosteronism [15]. High 
renin and aldosterone levels are reported in serum hormonal assays 
of these patients. Sodium wasting distinguishes this condition 
from PHA type 2 (also called familial hyperkalemic hypertension 
or Gordon’s syndrome) [16,17]. Urinary tract anomalies mostly 
cause secondary types in neonates [18,19]. Life-threatening 
consequences of this uncommon disease which can demonstrate 
itself with a broad spectrum of initial signs and symptoms made 
this unique case valuable to report to decrease the possibility of 
the under treatment or delayed treatment in a similar patient.
CASE REPORT
A 3-h-old male infant was admitted to the neonatology ward for 
high pitch cries, jitteriness, and mild tremors when disturbed 
and excessive sleep after formula-feeding. He was the product 
of the 2nd pregnancy of a non-consanguineous marriage. It was 
a full-term pregnancy, and the baby was delivered through 
cesarean section due to the previous history of the procedure. The 
1st cesarean section was performed because of the couple’s wish, 
without any medical indication. His birth weight was 3200 g with 
Apgar score of 9 and 10 at the 1st and 5th min, respectively.
Birth history indicated normal vital signs. No anatomical 
defects were mentioned. Genital organs included healthy 
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non-circumcised penis and descended testes. Mild bilateral 
hyperpigmentation of the nipples was noted. Maternal habitual 
history was positive for heroin addiction and methadone use as 
a rehabilitative medication. She continued heroin injections until 
delivery, and she passed away 36 h after giving birth due to a 
heroin overdose.
The infant was instantly hospitalized in the neonatology 
department. The modified Finnegan Neonatal Abstinence score 
of 6 was calculated [20]. Toxicology results were positive for 
morphine. Methamphetamine assessments on the 1st day and 
morphine on the 6th day were negative. The oncall pediatrician 
ordered loading and maintenance doses of intravenous 
phenobarbital with adequate hydration and continuous abstinence 
syndrome scoring. During admission, the patient had no seizure 
or epileptic signs, and his recorded abstinence scores never 
surpassed 3. There were no abnormal neurologic findings. 
Phenobarbital was changed to oral form.
Viral markers (antibodies and antigens) for Hepatitis B, 
Hepatitis C, and HIV were all negative. The patient had 
several episodes of post-feeding vomiting. Abdominopelvic 
ultrasonography revealed gastroesophageal reflux and did not yield 
any specific diagnosis. No whirlpool sign in midgut was reported. 
On the 3rd day of admission, a course of single surface phototherapy 
was started due to transient indirect hyperbilirubinemia with 
a total bilirubin of 6.2 mg/dl [0.1-1.2] and direct bilirubin of 
0.28 mg/dl [0.0-0.4]. Normal ranges of laboratory data are shown 
inside the brackets after each respectively Table 1. On the 5th day, 
the infant had a hypoglycemic attack which was managed with the 
administration of dextrose saline serum.
On the day 9, laboratory data revealed hyperkalemia 
(K+ = 7 mEq/L [normal 3.5-5.5]) with mixed respiratory alkalosis and 
metabolic acidosis (PH: 7.42, Pco2: 22 mmHg, Hco3: 12 mmol/L) 
and blood pressure of 84/44 mmHg were recorded. The infant had 
adequate urinary output with normal urinalysis. No changes in 
electrocardiography (ECG) occurred. Treatment of hyperkalemia 
immediately initiated by the following orders though it showed a 
slight resistance to the first-line steps. The entire potassium intake 
of the neonate was immediately cutoff. Calcium gluconate 10% 
(1 cc/kg) and bicarbonate were administered. After a slight response 
to treatment, once again on the day 10, potassium level was elevated 
(K+ = 6.9 mEq/L) with an accompanying simultaneous hyponatremia 
(Na = 133 mEq/L [135-145]). Hormonal assays were collected 
(17-OH Progesterone: 19. 7 ng/ml [0.2-0.8 ng/ml], Cortisol 8 AM: 
477.27 nmol/L [140-700 nmol/L]) and congenital adrenal hyperplasia, 
a common differential diagnosis in neonatal hyperkalemia, was ruled 
out Table 2 and 3. Elevated direct renin of 445 µIU/ml [2.8-39.9]) 
and aldosterone of 420 pg/ml [10-180] were noted. In addition to 
calcium gluconate, hydrochlorothiazide and furosemide were added 
to the medication list to overcome hyperkalemia.
Antibiotics were started after development of pneumonia 
and para-hilar haziness of the right lung on chest radiography. 
Potassium levels did not respond well to treatment and 
continuously fluctuated. In light of the laboratory (transtubular 
transient potassium gradient [TTKG >7, mild hyponatremia) 
and clinical findings (refractory hyperkalemia), PHA with a salt 
wasting pattern was the most probable diagnosis for this patient. 
No parental history of electrolyte disturbances was found. 
Hydrocortisone and fludrocortisone were added to his treatment 
regimen. The kidneys, bladder, and adjacent of urinary structures 
appeared normal finding on ultrasonography.
On the 20th day, hyperkalemia (K+ = 7.5 m Eq/L)-induced 
cardiac arrhythmia was demonstrated in the 2nd lead ECG. 
Eventually, oral kayexalate 1 mg/kg in 2 doses was started which 
decreased the potassium and increased sodium levels successfully. 
Unfortunately, while the medical team was in the middle of the 
diagnostic and therapeutic process, the infant was discharged at 
his father’s will, and therefore, genetic assessments could not be 
carried out. High sodium and low potassium diet were advised for 
the infant and family refused any other medical treatment.
DISCUSSION
In the past 50 years and since the 1st description of PHA type I, 
different inheritance patterns were discovered (autosomal 
dominant or autosomal recessive) [1,2,5]. Aldosterone is the 
principal mineralocorticoid for maintaining the hydration, 
essential fluid volume, and physiologic electrolyte balance. 
Hypovolemia or hyperkalemia provoke its secretion which leads 
mainly to reabsorption of sodium. Malfunctioning of ENaC or 
intracytoplasmic MR results in failure of aldosterone’s effect on 
the renal cortex [7]. In contrast to the autosomal recessive type, 
Table 1: Na (sodium) [135-145], K (potassium) [3.5-5.5], 
BS (Glucose) [<130], and Ca (Calcium)-[8.5-12.5] levels in blood 
samples of the patient
Days 
after 
birth
Na (mEq/L) K (mEg/L) BS (mg/dl) Ca (mg/dl)
1 138 4 88 9.4
3 138 3.8 75 8.6
9 136 7 45 8.9
10 139 4.8 72 9.7
11 133 6.9 62 9.5
12 135 4.3 95 -
13 132 5.2 92 10.2
14 132 6.9 140 -
15 130 6 77 -
16 132 5.7 107 -
17 131 5 92 -
18 131 5.9 102 -
19 - 4.3 62 -
19.5 132 6.1 120 -
20 133 7.3 - -
21 132 5.8 - -
21.5 136-137 3.9-4.2 - -
22 - 6.1 - -
22.5 139 4.2 - -
23 135 3.3 - -
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the autosomal dominant type results in less salt wasting and less 
systemic symptoms with more possibility of self-cure if the patient 
survives the critical first 6 months of life. This condition is mainly 
due to the development of proximal reabsorption of sodium in 
renal tubules [7]. Therefore, it is decisive to genetically prove the 
diagnosis of the autosomal recessive type to start the appropriate 
treatment and to inform the family about the prognosis.
In this case, TTKG levels were diagnostic for a malfunction 
in the mineralocorticoid system and the high aldosterone level in 
proof of resistance on the renal level. Initially, it was considered 
that secondary PHA which is more prevalent could describe the 
occurrence of symptoms. However, normal results of renal and 
pelvic sonography plus a lack of persistent hypoglycemia and 
hypertension along with no evidence of urinary tract infection 
ruled out this hypothesis.
As there were no clinical findings by high blood pressure, 
hyperchloremic metabolic acidosis, and volume expansion, 
PHA type II was excluded from the study. Obviously, there is 
no benefit to administering mineralocorticoids for patients with 
type 1 of the disease. Several medication regimens were used to 
control hyperkalemia in our patient and eventually hyperkalemia 
was maintained after adding oral kayexalate 1 g/kg in 2 doses per 
day. Patients with refractory hyperkalemia are always at great risk 
for arrhythmia and sudden death. However, our patient did not 
show any changes in ECG until day 20 when his ECG developed 
signs of hyperkalemia.
Properly adjusted doses of sodium chloride supplements, 
potassium-lowering treatments such as calcium gluconate, 
sodium bicarbonate, and potassium resin exchange, are the most 
relevant procedures to control the initial symptoms of PHA type I. 
Table 2: Complete blood count of the patient during hospitalization
Days after birth 1 5 9 21 Reference ranges
White blood cells (1000 C/ml) 15.6 8.5 14.1 16.6 Birth: 9.0-30.0
1-7 days: 9.4-34.0
8-14 days: 5.0-21.0
15 days-1 month: 5.0-20.0
Neutrophils (%) 70.4 55.1 56 90.6
Lymphocytes (%) 23.4 35.2 38 9.4
Mixed cells (%) 6.2 - 15.1 -
Band cells (%) - - 3 -
Red blood cells (Mil C/ml) 5.05 4.24 4.06 2.67 Birth: 3.90-5.50×10 (12)
1-7 days: 3.90-6.00×10 (12)
8-14 days: 3.60-6.00
15 days-1 month: 3.00-5.50 
Hematocrit (%) 55.20 45.2 42.1 26.8 Birth-7 days: 42.0-60.0 (%)
8-14 days: 39.0-60.0 (%)
15 days-1 month: 31.0-55.0 (%)
Hemoglobin (gr/dl) 19,7 15.5 15 9.1 birth-7 days: 13.5-22.0
8-14 days: 12.5-21.0
15 days-1 month: 10.0-20.0
Red blood cell distribution width (%) 23 21.6 19.8 17.5 <2 years: not established
Mean corpuscle volume (fl) 109.3 106 103 100.4 Birth: 98.0-120.0
1-7 days: 88.0-120.0
8-14 days: 86.0-120.0
15 days-1 month: 85.0-110.0
Platelets count (1000 C/ml) 323 348 622 398 150-350
Table 3: Additional laboratory data of patient during investigations
Days after birth 1 3 5 9 12 14 21 Reference range
ESR 1 h (mm/h) - - - 3 - - 10 Newborn: 0-2
neonatal: 3-13
Urea (mg/dl) 19 - 15 12 16 20 29 11-45
Creatinine (mg/dl) 1.1 - 0.6 0.62 0.67 0.61 0.5 0.4-1.4
T4/EIA (micg/dl) - - - 8.9 - - - 4.7-12.6
TSH (micIU/mL) - - - 1.1 - - - 0.3-6.5
Free T4 (ng/dl) - - - 0.8 - - - 0.8-2.3
Total bilirubin (mg/dl) - 6.2 - - - - - 0.1-1.2
Direct bilirubin (mg/dl) - 0.28 - - - - - 0.0-0.4
CRP (Qual) - - Negative Negative - - 3+Positive Negative
ESR: Erythrocyte sedimentation rate, T4: Thyroxine, EIA: Enzyme immunoassay, TSH: Thyroid-stimulating hormone, CRP: C-reactive protein
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Close follow-up intervals with electrolyte monitoring should be 
considered in babies [21]. Previously, very few cases of PHA type I 
had been reported in Iran. No scientific manuscript confirmed the 
diagnosis by genetic assay and subtype classification was not 
performed in other studies [22].
CONCLUSION
PHA type 1 is one of the rare but life-threatening causes of 
neonatal hyperkalemia. Initial therapy can prevent the possible 
occurrence of sudden death. After ruling out more common 
etiologies, aforementioned clinical features (sodium wasting, 
hyperkalemia, and hypovolemia) along with elevated levels of 
aldosterone and plasma renin activity are sufficient for diagnosis 
and prompt treatment.
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